Shares of Novavax (NVAX, Financial) experienced a significant decline, dropping more than 19% to $10.16. This downturn followed the U.S. Food and Drug Administration's (FDA) decision to suspend Novavax's planned clinical trial for a flu vaccine. The suspension was instigated by an adverse event reported in a participant of a separate Phase 2 trial, who suffered from a severe motor neuropathy incident.
NVAX Stock Plummets Over 19% Following FDA Trial Suspension
Oct 16, 2024
Disclosures
I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers